Roger Perlmutter, Merck
July 30, 2019 08:09 AM EDTUpdated 12:07 PM
Bioregnum
Opinion

Do you want to see what win­ning big in the R&D race looks like in the Big Phar­ma league?

Mer­ck $MRK of­fered a sim­ple les­son in the eco­nom­ics of win­ning a megablock­buster R&D race to­day. And it shouldn’t be missed by any­one.

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times